UroGen Pharma Ltd. (URGN)Healthcare | Biotechnology | Princeton, United States | NasdaqGM
22.54 USD
+1.15
(5.376%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 22.54 Short-term: ★★★☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:09 p.m. EDT
Despite weak intermediate-term forecasting statistics, the structural call OI buildup at multiple strikes and the 'Strong Buy' analyst consensus align to suggest a trend reversal. The market is pricing in a >40% upside target ($55) based on the 2026-05-15 and 2026-06-18 flow, with the short-term model's -2.3% prediction likely failing to account for the upcoming Phase 3 data catalyst positivity and the heavy options positioning at higher strikes. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.103606 |
| AutoARIMA | 0.103609 |
| AutoTheta | 0.109177 |
| MSTL | 0.127733 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 45% |
| H-stat | 7.97 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.346 |
| Excess Kurtosis | -0.99 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 2.282 |
| Market Cap | 1,097,298,688 |
| Forward P/E | 21.67 |
| Beta | 1.44 |
| Profit Margins | -139.81% |
| Website | https://www.urogen.com |
As of April 18, 2026, 10:09 p.m. EDT: Options market shows a clear bullish divergence. Call Open Interest (OI) is heavily front-loaded in OTM strikes (2026-06-18: +24.2% flow at 28 strike, 2026-05-15: +55.3% flow at 35 strike) combined with massive OTM OI buildup in longer-dated wings (Jan 2028 has >400 OI at 25 strike vs only 23 at 22 strike). Put OI is concentrated ITM (2026-08-21: 99% OTM OI, but heavy flow at 18/19 strikes), suggesting downside protection via crosses or hedging rather than pure speculation on a crash. The call skew (higher IV on OTM calls) indicates strong speculative positioning for upside momentum.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.3333333 |
| Address1 | 400 Alexander Park Drive |
| Address2 | 4th Floor |
| All Time High | 69.568 |
| All Time Low | 3.42 |
| Ask | 22.62 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 770,880 |
| Average Daily Volume3 Month | 775,708 |
| Average Volume | 775,708 |
| Average Volume10Days | 770,880 |
| Beta | 1.439 |
| Bid | 22.47 |
| Bid Size | 1 |
| Board Risk | 2 |
| Book Value | -2.181 |
| City | Princeton |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 22.54 |
| Current Ratio | 4.008 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 22.69 |
| Day Low | 22.0 |
| Display Name | UroGen Pharma |
| Earnings Call Timestamp End | 1,772,463,600 |
| Earnings Call Timestamp Start | 1,772,463,600 |
| Earnings Timestamp | 1,772,458,200 |
| Earnings Timestamp End | 1,778,589,000 |
| Earnings Timestamp Start | 1,778,589,000 |
| Ebitda | -124,556,000 |
| Ebitda Margins | -1.1345099 |
| Enterprise To Ebitda | -8.887 |
| Enterprise To Revenue | 10.082 |
| Enterprise Value | 1,106,929,536 |
| Eps Current Year | -1.05889 |
| Eps Forward | 1.04 |
| Eps Trailing Twelve Months | -3.19 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 19.7806 |
| Fifty Day Average Change | 2.7594013 |
| Fifty Day Average Change Percent | 0.1395004 |
| Fifty Two Week Change Percent | 133.33333 |
| Fifty Two Week High | 30.0 |
| Fifty Two Week High Change | -7.459999 |
| Fifty Two Week High Change Percent | -0.24866663 |
| Fifty Two Week Low | 3.42 |
| Fifty Two Week Low Change | 19.12 |
| Fifty Two Week Low Change Percent | 5.5906434 |
| Fifty Two Week Range | 3.42 - 30.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,493,904,600,000 |
| Float Shares | 38,656,651 |
| Forward Eps | 1.04 |
| Forward P E | 21.673079 |
| Free Cashflow | -99,423,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 291 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.88663 |
| Gross Profits | 97,341,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.037469998 |
| Held Percent Institutions | 0.99349 |
| Implied Shares Outstanding | 48,682,280 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey. |
| Long Name | UroGen Pharma Ltd. |
| Market | us_market |
| Market Cap | 1,097,298,688 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_240702165 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -153,494,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,098,759,059 |
| Number Of Analyst Opinions | 9 |
| Open | 22.02 |
| Operating Cashflow | -162,444,000 |
| Operating Margins | -0.50519 |
| Overall Risk | 2 |
| Payout Ratio | 0.0 |
| Phone | 646 768 9780 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 22.54 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 21.39 |
| Price Eps Current Year | -21.286442 |
| Price Hint | 2 |
| Price To Book | -10.334709 |
| Price To Sales Trailing12 Months | 9.994705 |
| Profit Margins | -1.39809 |
| Quick Ratio | 3.308 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 1.15 |
| Regular Market Change Percent | 5.37635 |
| Regular Market Day High | 22.69 |
| Regular Market Day Low | 22.0 |
| Regular Market Day Range | 22.0 - 22.69 |
| Regular Market Open | 22.02 |
| Regular Market Previous Close | 21.39 |
| Regular Market Price | 22.54 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 593,095 |
| Return On Assets | -0.32104 |
| Revenue Growth | 0.54 |
| Revenue Per Share | 2.282 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 48,682,280 |
| Shares Percent Shares Out | 0.1715 |
| Shares Short | 8,348,466 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 8,018,559 |
| Short Name | UroGen Pharma Ltd. |
| Short Percent Of Float | 0.174 |
| Short Ratio | 9.29 |
| Source Interval | 15 |
| State | NJ |
| Symbol | URGN |
| Target High Price | 55.0 |
| Target Low Price | 16.0 |
| Target Mean Price | 36.11111 |
| Target Median Price | 35.0 |
| Total Cash | 120,456,000 |
| Total Cash Per Share | 2.474 |
| Total Debt | 130,087,000 |
| Total Revenue | 109,788,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.19 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 19.950575 |
| Two Hundred Day Average Change | 2.589426 |
| Two Hundred Day Average Change Percent | 0.12979205 |
| Type Disp | Equity |
| Volume | 593,095 |
| Website | https://www.urogen.com |
| Zip | 8,540 |